TY  - BOOK
AU  - Gabbuat, Sheena Angela V.
AU  - Gonzales, Jan Chloe C.
AU  - Gumangan, Inah Marie O.
AU  - Inocalla, John Alexander M.
AU  - Mandawe, Joshua P.
AU  - Masula, Fredline Jean T.
AU  - Mercado, Dominique Vivien L.
AU  - Mosquite, Christine Anne C.
AU  - Muto, Kikoi C.
AU  - Orias, Sam Luigi E.
AU  - Pascual, Jhovan C.
AU  - Piansay, Joanna Marie D.
AU  - Pornillos, Britley Anne H.
AU  - Quanico, Mark Christopher G.
AU  - Ramiro, Jericho Marlowe V.
AU  - Rimando, Carlo Angelo B.
AU  - Santonia, Bless Faith S.
AU  - Tabilog, Angelo
AU  - Tangco, Mykel Jae
AU  - Tolentino, Patricia Mae T. 
AU  - Umil, Charisse Len
AU  - Yomo, Katrina Beatrice L.
AU  - Tagayuna, Pedrito, MD.
ED  - 
TI  - Therapeutic plasma exchange for patients with early and middle stage alzheimer's disease: a meta-analysis / 
AV  - M CFM 2020 0026 
PY  - 2020///
CY  - Fairview, Quezon City
PB  - Department of Community and Family Medicine, FEU-NRMF
KW  - therapeutic plasma exchange
KW  - plasmapheresis
KW  - meta-analysis
KW  - alzheimer's disease
KW  - middle stage alzheimer's disease
KW  - moderate alzheimer's disease
N1  - Includes bibliographical references; THDCFM
N2  - Abstract:  Alzheimer's disease is an irreversible and progressive neurodegenerative disorder that affects millions of elderly people globally. It is the most common cause of dementia and is, at the current time, untreatable. A limited number of traits have been conducted to find a potential treatment, the most recent being the therapeutic plasmapheresis. The objective of this report was to conduct a meta-analysis of articles discussing plasma exchange intervention for patients with both early and middle stage Alzheimer's Disease.  A handful of published English journals and articles were included in this meta-analysis of placebo controlled studies and randomized blinded plasma exchange published between 2016 and 2020. The studies were lifted from reputable databases such as PubMed and Science Direct. Included studies were those that involved patients between 55 to 85 years old with MMSE range of 18-26 and ADAS-Cog-based efficacy measurement. Contraindications to plasma exchange therapy were excluded. Outcomes were tabulated to be differentiated based on this study's objectives.  Of the 32 identified studies, only 2 studies were deemed eligible for detailed review. The included studies involved 389 participants all in all in a randomized fashion of 4 groups. 3 of these groups were given active treatment of 5% Albumin as high-volume plasma exchange, and 20% Albumin and IVIG as low-volume plasma exchange. The remaining group served as the control with placebo treatment. Across all meta-analysis, patients treated with PE showed significant improvement than the placebo group. Furthermore, the AMBAR trial exhibited that there was a significant difference in moderate AD patients over the control, while mild AD patients had no significant improvement against the control. The intervention used in  the study yielded no untoward side effects.  The study was limited only to one category of AD diagnosis, so the full extent of the disorder cannot be investigated. Bias may have been introduced by the articles in the event of deliberate incomplete reporting to prevent negative findings. In conclusion the results of the AMBAR Study suggest that Alzheimer's disease patients would benefit from the therapeutic plasma exchange, and there is still room for improvement wherein further research can be warranted.
ER  -